Anebulo Pharmaceuticals, Inc. (ANEB)
ANEB moved a median of -0.50% 30 minutes after news, and 0.00% by the close. How ANEB actually reacts to news — the realized, point-in-time move the market made, measured across 118 labeled events over the last three years with zero look-ahead.
ANEB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.98% | 16% | 67 |
| 30-min | -0.50% | 34% | 91 |
| 60-min | -0.54% | 37% | 95 |
| to close | 0.00% | 43% | 118 |
| Middle 50% of ANEB reactions | -1.79% to +0.49% |
|---|---|
| Median reaction (30-min) | -0.50% |
| Measured reactions | 118 |
Half of all Anebulo Pharmaceuticals, Inc. news events land between -1.79% and +0.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ANEB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANEB's baseline. Nothing else.
Recent ANEB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Anebulo Pharmaceuticals, | SEC filing · Form 15-12G | SEC EDGAR | -1.44% | -17.70% | |
| Form 25 Anebulo Pharmaceuticals, | SEC filing · Form 25 | SEC EDGAR | -2.18% | +1.39% | |
| Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates | Press release | Business Wire | — | +3.01% | |
| Form 10-Q Anebulo Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +3.01% | |
| Form 8-K Anebulo Pharmaceuticals, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | — | +3.01% | |
| Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC | Press release | Business Wire | +18.18% | +13.72% | |
| Form 8-K Anebulo Pharmaceuticals, For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | +18.18% | +13.72% | |
| Anebulo Pharmaceuticals Announces Final Results of Tender Offer | Press release | Business Wire | -1.11% | +2.35% | |
| Form 8-K Anebulo Pharmaceuticals, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | -1.11% | +2.35% | |
| Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer | Press release | Business Wire | -4.04% | -8.07% | |
| Form 8-K Anebulo Pharmaceuticals, For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | -4.04% | -8.07% | |
| Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer | Press release | Business Wire | -2.66% | -8.51% | |
| Form 8-K Anebulo Pharmaceuticals, For: Dec 22 | SEC filing · Form 8-K | SEC EDGAR | -2.66% | -8.51% | |
| Form PRER14A Anebulo Pharmaceuticals, | SEC filing · Form PRER14A | SEC EDGAR | +0.00% | -2.52% | |
| Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates | Press release | Business Wire | -1.64% | +2.46% | |
| Form 10-K Anebulo Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -1.64% | +2.46% | |
| Form 8-K Anebulo Pharmaceuticals, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | +2.46% | |
| Form S-8 POS Anebulo Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -1.24% | |
| Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity | Press release | Business Wire | +0.20% | +0.00% | |
| Form EFFECT Anebulo Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -1.63% | -0.41% | |
| Form POS AM Anebulo Pharmaceuticals, | SEC filing · Form POS | SEC EDGAR | -0.98% | -3.13% | |
| Form PRER14A Anebulo Pharmaceuticals, | SEC filing · Form PRER14A | SEC EDGAR | +1.01% | -0.41% | |
| Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives | Press release | Business Wire | -1.06% | +0.42% | |
| Form 8-K Anebulo Pharmaceuticals, For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | -1.06% | +0.42% | |
| Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock | Press release | Business Wire | -2.77% | +2.46% | |
| Form 8-K Anebulo Pharmaceuticals, For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -2.77% | +2.46% | |
| Form PRE 14A Anebulo Pharmaceuticals, For: Jul 23 | SEC filing · Form PRE | SEC EDGAR | -2.77% | +2.46% | |
| Form S-8 Anebulo Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | — | +0.99% | |
| Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates | Press release | Business Wire | — | -2.00% | |
| Form 10-Q Anebulo Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -2.00% | |
| Form 8-K Anebulo Pharmaceuticals, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | — | -2.00% | |
| Form 8-K Anebulo Pharmaceuticals, For: Apr 11 | SEC filing · Form 8-K | SEC EDGAR | — | +9.04% | |
| Form 8-K Anebulo Pharmaceuticals, For: Apr 11 | SEC filing · Form 8-K | SEC EDGAR | — | -3.06% | |
| Form 8-K Anebulo Pharmaceuticals, For: Apr 04 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form ARS Anebulo Pharmaceuticals, For: Jun 30 | SEC filing · Form ARS | SEC EDGAR | — | -2.86% | |
| Form DEF 14A Anebulo Pharmaceuticals, For: Mar 06 | SEC filing · Form DEF | SEC EDGAR | — | -2.86% | |
| Form EFFECT Anebulo Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -4.31% | |
| Form 8-K Anebulo Pharmaceuticals, For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | — | +0.82% | |
| Form PRE 14A Anebulo Pharmaceuticals, For: Feb 24 | SEC filing · Form PRE | SEC EDGAR | — | +0.82% | |
| Form S-3 Anebulo Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | — | -10.64% | |
| Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates | Press release | Business Wire | +0.00% | +0.00% | |
| Form 10-Q Anebulo Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Anebulo Pharmaceuticals, For: Feb 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Anebulo Pharmaceuticals, For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.13% | |
| Form D Anebulo Pharmaceuticals, | SEC filing · Form D | SEC EDGAR | +0.00% | -2.89% | |
| Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise | Press release | Business Wire | -11.24% | +20.19% | |
| Form 8-K Anebulo Pharmaceuticals, For: Dec 22 | SEC filing · Form 8-K | SEC EDGAR | +1.82% | +47.27% | |
| Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates | Press release | Business Wire | — | -9.52% | |
| Form 10-Q Anebulo Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -9.52% | |
| Form 8-K Anebulo Pharmaceuticals, For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | — | -9.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANEB section they belong to.
Where else ANEB is measured.
ANEB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Anebulo Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ANEB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 118 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 34% of ANEB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANEB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.